Tissue engineering/regenerative medicine ventures should invest early in market research to understand the future market's needs

Editorial

Chris Gemmiti. Tissue Eng Part B Rev. 2013 Apr.

. 2013 Apr;19(2):97-8.

doi: 10.1089/ten.TEB.2012.0728. Epub 2013 Feb 19.

No abstract available

Similar articles

Regenerative medicine 2.0.
Mason C. Mason C. Regen Med. 2007 Jan;2(1):11-8. doi: 10.2217/17460751.2.1.11. Regen Med. 2007. PMID: 17465770 No abstract available.
Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.
Bertram TA, Tentoff E, Johnson PC, Tawil B, Van Dyke M, Hellman KB. Bertram TA, et al. Tissue Eng Part A. 2012 Nov;18(21-22):2187-94. doi: 10.1089/ten.TEA.2012.0186. Epub 2012 Sep 27. Tissue Eng Part A. 2012. PMID: 22838399
[Collaboration between academia and companies].
Ueda M. Ueda M. Nihon Rinsho. 2008 May;66(5):997-1002. Nihon Rinsho. 2008. PMID: 18464523 Review. Japanese.
[Social effects in regenerative medicine].
Miyake J. Miyake J. Nihon Rinsho. 2008 May;66(5):1004-12. Nihon Rinsho. 2008. PMID: 18464524 Review. Japanese.
Regenerative medicine and the developing world.
Greenwood HL, Singer PA, Downey GP, Martin DK, Thorsteinsdóttir H, Daar AS. Greenwood HL, et al. PLoS Med. 2006 Sep;3(9):e381. doi: 10.1371/journal.pmed.0030381. PLoS Med. 2006. PMID: 16968130 Free PMC article. Review.